Angiogenesis Inhibitors: all 4,430 studies that test it
Page 42 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.
- Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid TumorsCompletedNCT00276575Phase 1
- Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue SarcomaCompletedNCT00276055Phase 1
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative DisorderCompletedNCT00274820Phase 2
- SU11248 as Consolidation After Response to Taxanes in Metastatic Breast CancerCompletedNCT00270413Phase 2
- Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00268489Phase 2
- Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory GliomasCompletedNCT00268359Phase 2
- Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)CompletedNCT00265824Phase 3
- Higher Frequency Zoledronic Acid in the Treatment of Multiple MyelomaCompletedNCT00263484Phase 2
- Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic CancerCompletedNCT00260364Phase 1/2
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT00258245Phase 1
- Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00255762Phase 2
- Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT00254319Phase 2
- Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic CancerWithdrawnNCT00253526Phase 2
- Lenalidomide and Docetaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00253344Phase 1
- A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS TumorsCompletedNCT00251797Phase 1
- A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLCCompletedNCT00251524Phase 2
- A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT00251459Phase 3
- Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT00250796Phase 2
- Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate CancerWithdrawnNCT00244920Phase 2
- PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic MelanomaCompletedNCT00238329Phase 2
- Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma PatientsCompletedNCT00232934Phase 3
- Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT00231140Phase 2
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00227682Phase 2
- A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell CarcinomaCompletedNCT00226980Phase 2
- Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver ReserveTerminatedNCT00225290Phase 3
- Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic CancerCompletedNCT00222469Phase 2
- IFM 99-02 Thalidomide in MyelomaCompletedNCT00222053Phase 3
- Thalidomide to Patients With Previously Untreated Multiple MyelomaCompletedNCT00218855Phase 3
- Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion LymphomaCompletedNCT00217503Phase 2
- Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung CancerCompletedNCT00217282Phase 2
- Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's DiseaseTerminatedNCT00209014Phase 2
- A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and NeckCompletedNCT00203905Phase 2
- An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate CancerCompletedNCT00201357Phase 2
- Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary SiteCompletedNCT00193622Phase 2
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple MyelomaCompletedNCT00193544Phase 2
- OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00193154Phase 2
- Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast CancerTerminatedNCT00193102Phase 2
- Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary FibrosisCompletedNCT00189176Phase 1/2
- Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)Status unknownNCT00184015Phase 1/2
- Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With TransplantCompletedNCT00182663Phase 2
- Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem GliomaCompletedNCT00179881Phase 2
- A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the PancreasTerminatedNCT00179751Phase 1/2
- A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.TerminatedNCT00179738Phase 2
- Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaTerminatedNCT00179725Phase 1/2
- Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaCompletedNCT00179712Phase 1/2
- Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung CancerTerminatedNCT00179699Phase 1
- A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung CancerCompletedNCT00179686Phase 2
- Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic ChemotherapyCompletedNCT00179608Phase 1
- Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal CarcinomaCompletedNCT00176774Phase 2
- Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast CancerCompletedNCT00174434Phase 1
- Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic AmyloidosisCompletedNCT00166413Phase 2
- Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal CancerCompletedNCT00165568Phase 2
- Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00165477Phase 2
- A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive CancerCompletedNCT00165451Phase 2
- rhEndostatin Protein Involving Pediatric Patients With CancerTerminatedNCT00165373Phase 1
- Thalidomide in Combination With Temodar in Patients With Neuroendocrine TumorsCompletedNCT00165230Phase 2
- Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal CarcinomaCompletedNCT00165217Phase 2
- Treatment of Idiopathic Pulmonary Fibrosis With ThalidomideCompletedNCT00162760Phase 2
- Bevacizumab in Advanced Hepatocellular CarcinomaStatus unknownNCT00162669Phase 2
- Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular CarcinomaStatus unknownNCT00155272Phase 1/2
- Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00153933Phase 1
- Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple MyelomaCompletedNCT00151203Phase 2
- Tetrathiomolybdate in Hormone Refractory Prostate CancerCompletedNCT00150995Phase 2
- Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung CancerStatus unknownNCT00150657Phase 2
- Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder CancerCompletedNCT00142480Phase 2
- Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular CarcinomaCompletedNCT00142467Phase 2
- Phase II Study Using Thalidomide for the Treatment of ALSCompletedNCT00140452Phase 2
- Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic MelanomaCompletedNCT00139360Phase 2
- A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular DegenerationTerminatedNCT00139282Phase 3
- Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated MesotheliomaCompletedNCT00137826Phase 2
- Avastin and Taxotere for Esophagogastric CancerCompletedNCT00137813Phase 2
- Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine TumorsCompletedNCT00137774Phase 2
- Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma PatientsCompletedNCT00127920Phase 2
- Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00126633Phase 2
- Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
- Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple MyelomaStatus unknownNCT00124813Phase 2
- Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal CancerTerminatedNCT00120172Phase 2
- Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar RadiculopathyCompletedNCT00120120Phase 2/3
- Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal CancerCompletedNCT00118261Phase 1
- Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung CancerCompletedNCT00118235Phase 2
- S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal CancerWithdrawnNCT00118105Phase 2
- Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal CancerCompletedNCT00116506Phase 2
- A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal CancerTerminatedNCT00114946Phase 4
- Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00114192Phase 2
- Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00114179Phase 2
- A Study of Tetrathiomolybdate in the Treatment of Psoriasis VulgarisCompletedNCT00113542Phase 2
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple MyelomaWithdrawnNCT00112879Phase 2
- Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00112528Phase 2
- UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory PatientsCompletedNCT00111748Phase 3
- A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast CancerCompletedNCT00109239Phase 3
- A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerCompletedNCT00109226Phase 2
- A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal CancerCompletedNCT00109070Phase 3
- An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer StudyCompletedNCT00109057Phase 2
- S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00104988Phase 2
- Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic SyndromesCompletedNCT00104962Phase 1
- Study Evaluating AMG 386 in Adult Patients With Advanced Solid TumorsCompletedNCT00102830Phase 1
- Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
- Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
- Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)TerminatedNCT00100685Phase 2
- Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With ChemotherapyCompletedNCT00099970Phase 2